Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …
in patients with viral respiratory diseases, and are currently being investigated in trials as …
Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management
COVID-19 pandemic is a serious concern in the new era. Acute respiratory distress
syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even …
syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even …
[PDF][PDF] Therapeutics and COVID-19: living guideline, 13 January 2023
World Health Organization - 2023 - apps.who.int
As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
[HTML][HTML] Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
JD Chalmers, ML Crichton… - European respiratory …, 2021 - Eur Respiratory Soc
Introduction Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …
Clinical practice guidelines from the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 convalescent plasma
Description: Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a
potential treatment of COVID-19. However, meta-analysis data and recommendations are …
potential treatment of COVID-19. However, meta-analysis data and recommendations are …
Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis
Objective To evaluate the efficacy and safety of antiviral antibody therapies and blood
products for the treatment of novel coronavirus disease 2019 (covid-19). Design Living …
products for the treatment of novel coronavirus disease 2019 (covid-19). Design Living …
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
Background Convalescent plasma has been widely used to treat COVID-19 and is under
investigation in numerous randomized clinical trials, but results are publicly available only …
investigation in numerous randomized clinical trials, but results are publicly available only …
Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
N Roche, ML Crichton, PC Goeminne… - European respiratory …, 2022 - Eur Respiratory Soc
Since the identification of SARS-CoV-2 at the end of 2019, the coronavirus disease 2019
(COVID-19) pandemic has affected more than 410 million people worldwide and killed …
(COVID-19) pandemic has affected more than 410 million people worldwide and killed …
Convalescent plasma treatment in patients with Covid-19: a systematic review and meta-analysis
A Jorda, M Kussmann, N Kolenchery… - Frontiers in …, 2022 - frontiersin.org
Convalescent plasma is a suggested treatment for Coronavirus disease 2019 (Covid-19),
but its efficacy is uncertain. We aimed to evaluate whether the use of convalescent plasma is …
but its efficacy is uncertain. We aimed to evaluate whether the use of convalescent plasma is …